Core Viewpoint - The approval of the "Biopharmaceutical Industry Chain Open Innovation Development Plan" by the State Council provides opportunities for Jiangsu Province to strengthen and expand its leading position in the biopharmaceutical industry during the 14th Five-Year Plan period [1] Group 1: Policy Recommendations - Strengthen integrated policy supply and enhance service effectiveness by implementing an "Excellence Cultivation Plan" for innovative pharmaceutical companies and optimizing clinical trial subsidy application processes [1] - Promote an "early intervention, rolling submission" approval pathway for innovative drugs and medical devices, and establish a "one product, one special class" service mechanism [1] - Establish a "white list" system for the import and export of research and development materials in biopharmaceuticals and streamline the approval process for drug marketing licenses and production licenses [1] Group 2: Innovation Ecosystem - Build a comprehensive innovation ecosystem to enhance core industry momentum by attracting national clinical medical research centers and major infrastructure projects to Jiangsu [1] - Accelerate the establishment of provincial smart pharmacy laboratories and leverage national university technology transfer centers to support the establishment of new R&D institutions [1] - Implement a green channel for the listing and coding of innovative medical devices and promote data governance across departments in healthcare [1] Group 3: Talent and Financial Support - Strengthen support for essential resources by establishing a joint recruitment and cross-training mechanism for top talents between research institutions and enterprises [1] - Include AI pharmaceutical algorithm engineers in the provincial key talent cultivation directory and develop a supporting system for high-end talent [1] - Innovate financing products to support the development of customized financial products such as intellectual property pledge loans and establish an international drug registration service center [1]

（来源：千龙网） 去年，科兴高精尖成果转化基地、国际精准医学产业园、生命谷国际生物工程创新中心三大标准化厂房 项目相继投用，在生命科学园三期地块上释放出65万平方米产业空间。截至1月底，生命谷国际生物工 程创新中心，已有15家创新企业确定或意向入驻，其中进展最快的企业已准备进场开展内部装修，预计 4月就能入驻办公。 寻找新的办公和研发空间迫在眉睫。也是这时，与中关村生命科学园一期一街之隔的国际精准医学产业 园，进入了于涛的视野。"不仅地理空间近，这里还延续了生命科学园的全链条服务能力，产业空间充 分考虑到承接医药产业的研发、小试、中试等需求。" 作为中关村生命科学园三期首个发布的项目，国际精准医学产业园总占地面积7.4公顷。走进园区，24.2 万平方米的建筑群错落有致，17栋产业组合空间如同串联创新要素的"珍珠"，构建起覆盖总部办公、研 发中心、中试基地、生产厂区的全链条载体。同时，园区周边还布局了55个共享服务平台，为创新成果 加速转化省去后顾之忧。"截至目前，园区已有15家企业完成入驻或意向签约，进展最快的企业已进场 办公。"昌发展康瑞公司总经理杨建宏介绍。 而从高空俯瞰犹如一株生命之树的科兴高精尖成果转 ...

Core Viewpoint - The stock of Insilico Medicine (03696) has risen over 4%, reaching a new high of 72.4 HKD, driven by significant milestone payments from its collaboration with Menarini Group for the MEN2501 project [1] Group 1: Financial Performance - Insilico Medicine received a milestone payment of 39 million HKD from Menarini Group after the first patient was dosed in the Phase I clinical trial of MEN2501 [1] - The company has achieved a total of 3 business development (BD) collaborations since 2026, with upfront payments totaling 42 million USD, including recent research milestone payments [1] - The total amount from these collaborations has reached 1.074 billion USD, indicating strong commercial validation of the company's value [1] Group 2: Product Development - MEN2501 is a highly differentiated KIF18A inhibitor designed and optimized by Insilico's generative AI engine, aimed at treating chromosomal instability solid tumors [1] - The core pipeline ISM001-055 is the only fully AI-developed drug to have obtained Phase II clinical data globally, with potential to become a disruptive therapy [1] - The company is expected to achieve more BD collaborations in 2026, which could act as a direct catalyst for stock price appreciation [1]

Core Viewpoint - The stock of Insilico Medicine (03696) has risen over 4%, reaching a new high of 72.4 HKD, driven by significant milestone payments from its collaboration with Menarini Group for the MEN2501 project [1] Group 1: Financial Performance - Insilico Medicine received a milestone payment of 39 million HKD from Menarini Group after the first patient was dosed in the Phase I clinical trial of MEN2501 [1] - The company has achieved a total of 3 business development (BD) collaborations since 2026, with upfront payments totaling 42 million USD, including recent milestone payments [1] - The total value of these collaborations amounts to 1.074 billion USD, indicating strong commercial validation of the company's value [1] Group 2: Product Development - MEN2501 is a highly differentiated KIF18A inhibitor designed and optimized by Insilico's generative AI engine, aimed at treating chromosomal instability solid tumors [1] - The core pipeline ISM001-055 is the only fully AI-developed drug to have obtained Phase II clinical data globally, with potential to become a disruptive therapy [1] - The company is expected to achieve more BD collaborations in 2026, which could serve as a direct catalyst for stock price growth [1]

Core Insights - The company is actively advancing the sales preparation for its influenza drug, Mapasavir capsules (Yilikan®), across various channels, with online sales launched on major e-commerce platforms and offline distribution in key pharmacies and hospitals [1][3] - The development of the pediatric formulation of Mapasavir, suitable for children aged 2-12, is progressing well, having entered Phase III clinical trials in November 2025 [4] - The TSLP monoclonal antibody, targeting moderate to severe COPD, is in Phase III clinical trials and is leading in progress compared to similar projects in China [5][6] - The Nav1.8 inhibitor for pain management has completed Phase I trials and is moving into Phase II, focusing on postoperative pain [7] - The company is leveraging AI technology across the drug development process, enhancing efficiency and innovation capabilities [8] - The company is making significant strides in international expansion, with projects in Vietnam, Indonesia, and the establishment of subsidiaries in the Philippines and the Netherlands [2][9] Sales and Marketing Strategy - The company is enhancing the accessibility of Mapasavir capsules through partnerships with online platforms and academic teams to educate healthcare providers and patients [3] - A comprehensive marketing strategy is being implemented to promote the pediatric formulation of Mapasavir, focusing on optimizing taste and dosage for better adherence [4] Research and Development - The TSLP monoclonal antibody is positioned to address unmet needs in COPD treatment, with a focus on reducing acute exacerbation rates [5][6] - The Nav1.8 inhibitor is strategically targeting a clear clinical need in postoperative pain management, which may shorten the overall development cycle [7] - AI applications are being integrated into various stages of drug development, from molecular discovery to commercial patient services [8] International Expansion - The acquisition of Vietnam's IMP company is progressing, aimed at strengthening the company's position in the Southeast Asian market [2][9] - The construction of a factory in Indonesia is underway, intended to produce specialty active pharmaceutical ingredients for the European and American markets [2][9] - The company is establishing a regulatory and sales framework in Southeast Asia and the EU, with successful GMP compliance checks in Malaysia [2][9]

智通财经APP获悉，西南证券发布研报称，预计英矽智能(03696)2025-2027年对应营业收入分别为 0.59、1.55和2.02亿美元，对应PS为78倍、30倍和23倍。公司AI平台创新能力得到验证，长期发展值得 期待，随着更多管线资产进入临床和对外授权，公司有望迎来持续的价值兑现。首次覆盖，建议积极关 注。 西南证券主要观点如下： 公司核心竞争力在于其自研的全球领先的端到端生成式AI平台Pharma.AI 1）该平台将从靶点发现到临床前候选化合物确认的时间从行业平均的4.5年缩短至12-18个月，已通过 40+的项目，27个PCC得到充分验证；2）公司主要业务模式为药物发现及管线开发，包括对外授权、合 作开发和自主开发，26年至今公司已达成3项BD合作，首付款达0.42亿美元（含近期研发里程碑），总 金额达10.74亿美元。随着公司商业价值得到验证，26年有望达成更多BD合作，带来股价的直接催化； 3）自主开发的核心管线ISM001-055为全球AI制药唯一一款取得Ⅱ期临床数据的全AI研发药物，未来有 望成为颠覆性疗法，迎来持续的价值兑现。 全球领先的端到端AI制药平台，构筑核心技术壁垒 公司核心竞争 ...

好的，各位投资人，晚上好，然后欢迎参加我们的医药每周谈第 236 期，关于 GP MOOC 2026 的海外公司的一个进展。然后我是中银建投医药分析师徐颖翔。然后就是关于整个 Gilead 海外公司的一个情况吧。我们可以看得出来，在整个基于摩根这个期间的话，海外 的药企主要就是在一个专利悬崖的一个压力下面，是加速转型与和与技术兑现。大部分跨 国药企的话，是通过一个大规模的 BD 和并购来平滑自己重磅产品专利的到期的一个销售 冲击。包括默沙东规划 700 亿美元的一个新的产品组合，BMS 的话这几年也完成了 300 亿美元的一个并购交易，阿斯利康的话也是目标在 2030 年能够实现一个 800 亿美元的一 个营收。 因此这几年的话，整个受并购与 BD 还是各家跨国药企最重要的一个战略布局的一个方向， 主要也就是为了应对专利悬崖，同时聚焦高确定性的资产，以及技术平台的一个补强。另 一方面的话，也是整个 AI，从工具也上升到了一个制药的一个核心生产力。成为整个制药 行业的一个核心的驱动，驱动力之一。多家跨国药企，包括礼来、阿斯利康、赛诺菲，都 在 GD Morgan 期间。通过与英伟达以及各种其他的 AI 公司达成 ...

机构：国海证券 研究员：曹泽运/万鹏辉 投资要点: 持续达成研发合作，AI 制药能力不断被认可2021 年至今，公司已于多家国内外龙头药企达成研发合 作，其中2022 年跟赛诺菲达成最高12 亿美元+特许权使用费合作，2025 年跟礼来达成超1 亿美元+特许 权使用费合作，2026 年与施维雅达成多年期抗肿瘤药物研发合作，协议总金额高达8.88 亿美元。多家 国内外龙头药企陆续跟公司达成AI 平台研发合作，公司AI 平台研发能力不断被认可。 已有多款自研管线对外授权2023 年至今，公司已经完成3 笔对外自主研发管线的对外授权，分别为： 2023 年对EXELIXIS 授权USP1 靶点药物，总金额接近10 亿美元，其中首付款8000 万美元；2023 年对 Menarini 授权KAT6 小分子，总金额超过5 亿美元，其中首付款1200 万美元；2024 年继续对Menarini 授 权，总金额超过5.5亿美元，首付款2000 万美元，2025 年12 月授权太景PHD 抑制剂ISM4808 大中华区 开发、商业化和再许可权力，交易总额达数千万美元，以上均包含特许权使用费。2026 年1 月，对衡泰 生物授 ...

智能体可在执行任务过程中模仿人的思维工作过程，进行自我反思、学习和改进，也是深度智耀技术平台的一大亮点。 深度智耀的过往合作案例中，由AI撰写的临床试验方案已实现一次性通过监管部门审批。 文 ｜ 胡香赟 编辑 ｜ 海若镜 封面来源 ｜ IC Photo 36氪获悉，AI制药独角兽企业深度智耀近期已完成6000万美元新一轮融资。本轮融资的新投资方包括信宸资本、金镒资本、凯泰 资本，老股东鼎晖百孚、新鼎资本持续追加，指数资本继续担任独家财务顾问。募集资金将主要用于核心技术体系升级。 值得一提的是，去年12月，深度智耀刚刚官宣一笔5000万美元的D轮融资。短短两月内，公司累计已拿到超一亿美元的融资。 当前，受限于技术能力等影响，大部分企业仍主要把AI应用于新药研发过程中的临床前阶段。相较之下，深度智耀则能为全球药 企提供从药物临床前研究、注册申报、临床试验到上市后研究的全栈式智能解决方案。据深度智耀方面介绍，过往合作案例中， 公司为客户提供的由AI"大脑"撰写临床试验方案已实现"零返修"，一次性通过监管部门的审批。 在制药行业，过去，市场往往更愿意为有确定性价值的管线资产买单，对单纯的技术平台抱有更审慎的态度。深度 ...

Core Insights - The Chinese biopharmaceutical industry experienced a historic leap in 2025, with 76 innovative drugs approved for market, a 58% increase from 2024, and total licensing transactions exceeding $130 billion, marking record highs in both transaction volume and value [1] - The "China strategy" has become a central topic at the JPM 2026 conference, highlighting the importance of global collaboration in the biopharmaceutical sector [2] Industry Developments - Chinese biopharmaceutical companies face significant challenges when entering markets like the US and Europe, including stringent regulatory requirements and high competition, with a success rate of only 0.4% for Chinese biopharmaceuticals from clinical phase I to market in the US [3] - The complexity of healthcare systems in Europe and the strict approval processes by the EMA further complicate market entry for Chinese firms [3] Transaction Trends - There has been a notable decline in cross-border License-in transactions from 2022 to 2025, while License-out transactions have surged, with the total value in 2025 being approximately 2.5 times that of 2024 [4] - New transaction structures such as the NewCo model and Royalty Monetization are emerging as preferred options for Chinese pharmaceutical companies, indicating a shift towards a more integrated global partnership approach [4][5] Future Outlook - The next 3-5 years are expected to be significant for business development (BD) in China's biopharmaceutical sector, with a strong recovery in financing and an optimistic outlook for international collaboration [7][8] - The industry is positioned to leverage its comprehensive R&D capabilities and cost advantages, with innovative drugs priced at about one-tenth of their US counterparts, suggesting a continued role as a source of global innovation [8]